Bottom line
PILL vs LABU: the short answer
PILL (Direxion Daily Pharmaceutical & Medical Bull 3X ETF) and LABU (Direxion Daily S&P Biotech Bull 3X ETF) are both etfs.
But LABU is far broader, holding 163 positions to 73 for PILL, so beyond the top names it adds exposure PILL doesn't have.
LABU is cheaper at 0.96% vs 0.98% — a difference of $2.00 a year per $10,000 invested.
Over five years, PILL returned −12.6% a year vs −39.6% for LABU.
Updated Nov 19, 2026
PILL vs LABU side by side
| PILL | LABU | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.98% | 0.96% |
| Annual cost per $10k | $98 | $96 |
| 10-yr cost on $10k (prospectus) | $1,456 | $1,178 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +75.0% | +78.7% |
| 5-yr return (annualized) | −12.6% | −39.6% |
| 10-yr return (annualized) | — | −20.8% |
| Best quarter | +103.7% | +161.5% |
| Worst quarter | −61.4% | −67.4% |
| Net assets (fund) | $20.7M | $494.4M |
| Number of holdings | 73 | 163 |
| Portfolio turnover | 88% | 107% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PILL | LABU | Difference |
|---|---|---|---|
| 2025 | +75.0% | +78.7% | −3.7% |
| 2024 | −6.9% | −25.9% | +19.0% |
| 2023 | −12.7% | −13.4% | +0.8% |
| 2022 | −43.1% | −80.3% | +37.2% |
| 2021 | −37.2% | −64.3% | +27.1% |
| 2020 | −0.3% | +74.7% | −75.0% |
| 2019 | +18.2% | +74.6% | −56.5% |
| 2018 | −19.6% | −57.3% | +37.7% |
Source: Fund prospectus bar charts
Holdings overlap
5 of PILL's top 25 holdings also appear in LABU's top 25.
| Holding | PILL | LABU |
|---|---|---|
| Goldman Financial | 22.36% | 14.83% |
| N/a | 16.36% | 3.87% |
| Dreyfus | 8.14% | 15.86% |
| N/a | 7.41% | 3.87% |
| Goldman Sachs Liq Es Fd A | 2.03% | 5.35% |
Source: SEC Form N-PORT
PILL top 10
- Goldman Financial — 22.36%
- N/a — 16.36%
- Dreyfus — 8.14%
- N/a — 7.41%
- Crinetics Pharmaceuticals In — 2.77%
- Mbx Biosciences Inc — 2.42%
- Ataibeckley Inc — 2.16%
- Definium Therapeutics, Inc — 2.13%
- Goldman Sachs Liq Es Fd A — 2.03%
- Amylyx Pharmaceuticals Inc — 1.72%
LABU top 10
- Dreyfus — 15.86%
- Goldman Financial — 14.83%
- N/a — 9.63%
- N/a — 7.30%
- Goldman Sachs Liq Es Fd A — 5.35%
- N/a — 4.85%
- N/a — 3.87%
- Apogee Therapeutics Inc — 1.11%
- Oruka Therapeutics Inc — 1.03%
- Dianthus Therapeutics Inc — 0.96%
FAQ
What is the difference between PILL and LABU?
Which is cheaper, PILL or LABU?
Should I own both PILL and LABU?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.